Form 4: Neurocrine Biosciences Director Receives Stock Grant
Insider Transaction (Form 4)
Kevin Charles Gorman, a Director of Neurocrine Biosciences Inc, reported multiple transactions in common stock on September 11, 2026.
Summary
- Grant/award: acquired 14,343 Common Stock on September 11, 2026; holds 525,636 after (Direct).
- Tax/exercise-price withholding: disposed of 7,839 Common Stock at $156.22 ($1,224,609) on September 11, 2026; holds 517,797 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kevin Charles Gorman — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-11 | Grant/award | Common Stock | 14,343 | — | — | 525,636 |
| 2026-09-11 | Tax/exercise-price withholding | Common Stock | 7,839 | $156 | $1.2M | 517,797 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-11 | Grant/award (14,343 shares) |
| 2026-09-11 | Tax/exercise-price withholding (7,839 shares) |
Keywords
insider transaction, Form 4, NBIX, NEUROCRINE BIOSCIENCES INC, neutral, Kevin Charles Gorman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.